Akurasi Spesivisitas dan Sensitivitas Angka RMI 2 Skor pada Penderita Tumor Ganas Ovarium di RSUP Dr. Hasan Sadikin Bandung Periode 2017−2018

Arieff Kustiandi, Yudi Mulyana Hidayat, R.M Sonny Sasotya, Andi Kurniadi

Abstract


Tujuan: Penelitian ini bertujuan untuk mengetahui spesifitas dan sensitivitas skor RMI 2 dalam  menentukan  keganasan ovarium. Kadar CA 125 dan skor RMI 2 diukur dari hasil pemeriksaan histopatologi digunakan sebagai pemeriksaan gold standard. Penelitian ini dilakukan pada periode Januari 2017−Desember 2018.
Metode: Penelitian ini menggunakan metode observasional analitik dengan rancangan cross sectional. Data kategorik diuji dengan uji chi-square atau  uji Exact Fisher. Data numerik digunakan  uji-t tidak berpasangan atau  uji Mann Whitney. Sumber data diperoleh dari rekam medis pasien di Poli Ginekologi Onkologi RSUP Dr. Hasan Sadikin Bandung berdasarkan angka skor RMI 2 pada penderita suspek tumor ganas ovarium.
Hasil: Sampel berjumlah 172 dengan  31 berkategori  jinak  dan 141 berkategori ganas berdasarkan hasil histopatologi. Hasil penelitian  menunjukkan  nilai median CA 125 kelompok ganas dibanding kelompok jinak (437, 05 vs 212,14) bermakna secara statistik p = 0,001 (nilai p<0,05). Cut of point skor  RMI 2 adalah >200 dengan sensitivitas 95,74% dan spesifisitas 16,12%.
Kesimpulan: Skor  RMI 2 adalah metode yang digunakan untuk memprediksi tumor ganas ovarium. Hal ini sangat berguna digunakan dengan  kombinasi CA 125 dengan hasil pemeriksaan ultrasonografi (USG) dan status menopause atau dikenal dengan Risk Malignancy Index (RMI skor 2 cut off point >200 ) dengan sensitivitas 95,74%, spesifisitas 16,12%dan akurasi 81,39 %. Skor RMI 2 mempunyai sensitivitas yang tinggi, tetapi mempunyai spesivisitas yang rendah, sehingga membutuhkan penelitian lebih lanjut.

Accuracy of Specificity and Sensitivity of RMI 2 Score Numbers in Ovarium Fanner Tumors in RSUP Dr. Hasan Sadikin Bandung Period 2017-2018

Abstract
Objective: This study aims to determine the specificity and sensitivity of RMI 2 score in ovarian malignancy. The CA 125 level and the RMI 2 score were measured and adjusted by histopathology examination as gold standard. This research was conducted in period January 2017−December 2018.
Methods: This research used observational analitic research method with cross sectional design. Categorical data were tested by chi-square test or Fisher's Exact test. Numerical data are used unpaired t-test or Mann Whitney test. The source of data from medical records of patients in Gynecology Oncology Clinic Dr. Hasan Sadikin Bandung based on the RMI 2 score with suspected ovarian malignant tumors.
Result: Samples were 172 with 31 benign categories and 141 malignant categories based on the results of histopathology. The results showed a median value of CA 125 of the malignant group compared to the benign group (437, 05 vs. 212.14) statistically significant p = 0.001 (p value <0.05). The RMI 2 score cut off point > 200 with a sensitivity of 95.74% and specificity of 16.12%.
Conclusion: This study is an RMI 2 score is a useful way as a predictor of ovarian malignancy. This is very useful to use with a combination of CA 125 with the results of ultrasonography (USG) and menopausal status or known as the Risk Malignancy Index (RMI score 2 cut off point> 200) with a sensitivity of 95.74%, specificity 16.12% and accuracy 81 , 39%. RMI 2 score has high sensitivity, but has low specificity, so it needs further research.

Key words: CA 125, RMI 2 score, ovarian malignancy


Keywords


CA 125, prediktor keganasan, RMI skor 2

Full Text:

PDF

References


Jyothi HR. Risk of malignancy index in assessment of pelvic mass. International Journal of Biomedical Research. IJBR (2014) 05 (03). 184-6.

Sinaga, FIK. Perbandigan Modifikasi Risk Of Malignancy Index (RMI) Dibanding Dengan RMI Dan Risk Of Ovarian Malignancy Algorythrm (ROMA) Dalam Prediksi Kanker Ovarium Tipe Epitel. 2016.

Karimi ZM, Mojaver SP, et al. Diagnostic Value of the Risk of Malignancy Index (RMI) for Detection of Pelvic Malignancies Compared with Pathology. Electron Physician. 2015;7(7):1505-10. Published 2015 Nov 20. doi:10.19082/1505.

Shia S. Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian Masses. JOINT SOGC/GOC/SCC. Clinical Practice Guideline. No. 230, July 2009.

Rujuta J. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass. J Obstet Gynaecol India. 2015 Apr; 65(2): 117–121.

Ghazali MV, Sastromiharjo S, Soedjarwo SR, Soelaryo T, Pramulyo HS. Studi Cros-sectional. Dasar-dasar Metodologi Penelitian Klinis. Jakarta. Ed 4. 2011. 130−144.

Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42(2):152-155.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012;67(5):437−441.

Dora SK, Dandapat AB, Pande B, Hota JP. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. J Ovarian Res. 2017;10(1):55.

Aziz AB, Najmi N. Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?. Obstet Gynecol Int. 2015;2015:951256.




DOI: http://dx.doi.org/10.24198/obgynia/v3n2.207

Refbacks

  • There are currently no refbacks.


Alamat Redaksi

 

KSM/Dep Obstetri & Ginekologi Fakultas Kedokteran Universitas Padjadjaran RSUP Dr. Hasan Sadikin

Jl. Pasteur No 38 Bandung 40161 

Telp: 0813-2012-9954

Email: obgyniajurnal@gmail.com

 

 

 




Indexed By
         



Web Analytics
View My Stats

Indonesian Journal of Obstetrics & Gynecology Science @2017